Literature DB >> 15650841

Long-term evaluation of isolation-rearing induced prepulse inhibition deficits in rats: an update.

J Cilia1, P D Hatcher, C Reavill, D N C Jones.   

Abstract

RATIONALE: Rats reared in social isolation from weaning show prepulse inhibition (PPI) deficits which are thought to model the sensorimotor gating deficits seen in schizophrenia and other psychiatric disorders. We have previously reported that ten cohorts of Lister Hooded rats reared in isolation showed robust and reliable PPI deficits.
OBJECTIVE: Our methodology differed from those used by others (Weiss and Feldon in Psychopharmacology 156(2-3):305-326, 2001), most notably in the weaning of pups at postnatal day (PND) 28 compared with PND20-22. Since our initial report, we have studied 18 more cohorts weaned at PND28 and one cohort weaned at PND21.
METHOD: At weaning, male Lister Hooded pups were singly (isolates) or group (n=5) housed (grouped). Eight weeks later, startle and PPI responses of isolates and grouped rats were investigated using conditions of fixed inter-stimulus interval (ISI) (pulse=110 dB/50 ms; prepulse (PP)=75-80 dB/30 ms; ISI=100 ms).
RESULTS: Isolates from 14 of the subsequent 18 cohorts demonstrated PPI deficits, giving an overall success rate of 86% for all 28 cohorts. %PPI ranged from 12 to 26% in the isolates and from 26 to 47% in the grouped for the successful cohorts, compared to 16-30% (isolates) and 19-35% (grouped) for those that failed. Only five out of the 19 subsequent cohorts demonstrated startle hyperreactivity, which was unrelated to PPI response. The isolates from the cohort weaned at PND21 did not show a significant deficit in PPI, suggesting, in our hands at least, a requirement for weaning at PND28.
CONCLUSION: The data presented here reinforce our original findings that isolation-rearing of Lister Hooded rats provides a viable, non-pharmacological model of impaired PPI.

Entities:  

Mesh:

Year:  2005        PMID: 15650841     DOI: 10.1007/s00213-004-2139-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  29 in total

1.  Impaired sensory gating and attention in rats with developmental abnormalities of the mesocortex. Implications for schizophrenia.

Authors:  L M Talamini; B Ellenbroek; T Koch; J Korf
Journal:  Ann N Y Acad Sci       Date:  2000-06       Impact factor: 5.691

2.  Long-term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonism.

Authors:  Laura Wiseman Harris; Trevor Sharp; Jane Gartlon; Declan N C Jones; Paul J Harrison
Journal:  Eur J Neurosci       Date:  2003-09       Impact factor: 3.386

3.  Impaired prepulse inhibition of acoustic startle in schizophrenia.

Authors:  A Parwani; E J Duncan; E Bartlett; S H Madonick; T R Efferen; R Rajan; M Sanfilipo; P B Chappell; S Chakravorty; S Gonzenbach; G N Ko; J P Rotrosen
Journal:  Biol Psychiatry       Date:  2000-04-01       Impact factor: 13.382

Review 4.  Sensorimotor gating and schizophrenia. Human and animal model studies.

Authors:  D L Braff; M A Geyer
Journal:  Arch Gen Psychiatry       Date:  1990-02

5.  Reflex modification in the domain of startle: I. Some empirical findings and their implications for how the nervous system processes sensory input.

Authors:  H S Hoffman; J R Ison
Journal:  Psychol Rev       Date:  1980-03       Impact factor: 8.934

6.  Gating and habituation of the startle reflex in schizophrenic patients.

Authors:  D L Braff; C Grillon; M A Geyer
Journal:  Arch Gen Psychiatry       Date:  1992-03

7.  Stability of the acoustic startle reflex, prepulse inhibition, and habituation in schizophrenia.

Authors:  Katja Ludewig; Mark A Geyer; Mario Etzensberger; Franz X Vollenweider
Journal:  Schizophr Res       Date:  2002-05-01       Impact factor: 4.939

8.  Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.

Authors:  C Reavill; S G Taylor; M D Wood; T Ashmeade; N E Austin; K Y Avenell; I Boyfield; C L Branch; J Cilia; M C Coldwell; M S Hadley; A J Hunter; P Jeffrey; F Jewitt; C N Johnson; D N Jones; A D Medhurst; D N Middlemiss; D J Nash; G J Riley; C Routledge; G Stemp; K M Thewlis; B Trail; A K Vong; J J Hagan
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

Review 9.  Schizophrenia: solving the puzzle.

Authors:  B D Kelly; E O'Callaghan; A Lane; C Larkin
Journal:  Ir J Med Sci       Date:  2003 Jan-Mar       Impact factor: 1.568

10.  The glycine/NMDA receptor antagonist, L-701,324 reverses isolation-induced deficits in prepulse inhibition in the rat.

Authors:  L J Bristow; L Landon; K L Saywell; M D Tricklebank
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

View more
  20 in total

1.  Neonatal phencyclidine administration and post-weaning social isolation as a dual-hit model of 'schizophrenia-like' behaviour in the rat.

Authors:  Philip L R Gaskin; Stephen P H Alexander; Kevin C F Fone
Journal:  Psychopharmacology (Berl)       Date:  2014-01-09       Impact factor: 4.530

Review 2.  Animal models of schizophrenia.

Authors:  C A Jones; D J G Watson; K C F Fone
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 3.  The family of sensorimotor gating disorders: comorbidities or diagnostic overlaps?

Authors:  Mark A Geyer
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

4.  Pharmacological characterization of social isolation-induced hyperactivity.

Authors:  Katrine Fabricius; Lone Helboe; Anders Fink-Jensen; Gitta Wörtwein; Björn Steiniger-Brach
Journal:  Psychopharmacology (Berl)       Date:  2010-12-31       Impact factor: 4.530

5.  In vivo neurometabolic profiling to characterize the effects of social isolation and ketamine-induced NMDA antagonism: a rodent study at 7.0 T.

Authors:  Antonio Napolitano; Khalid Shah; Mirjam I Schubert; Veronica Porkess; Kevin C F Fone; Dorothee P Auer
Journal:  Schizophr Bull       Date:  2013-05-13       Impact factor: 9.306

6.  Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040.

Authors:  Eric Southam; Jackie Cilia; Jane E Gartlon; Marie L Woolley; Laurent P Lacroix; Carol A Jennings; Jane E Cluderay; Charlie Reavill; Claire Rourke; David M Wilson; Lee A Dawson; Andrew D Medhurst; Declan N C Jones
Journal:  Psychopharmacology (Berl)       Date:  2008-09-03       Impact factor: 4.530

7.  Negative visuospatial priming in isolation-reared rats: Evidence of resistance to the disruptive effects of amphetamine.

Authors:  Nurith Amitai; Susan Powell; Martin Weber; Neal R Swerdlow; Jared W Young
Journal:  Cogn Affect Behav Neurosci       Date:  2015-12       Impact factor: 3.282

Review 8.  Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

Authors:  Jared W Young; Susan B Powell; Victoria Risbrough; Hugh M Marston; Mark A Geyer
Journal:  Pharmacol Ther       Date:  2009-03-06       Impact factor: 12.310

9.  Focusing on symptoms rather than diagnoses in brain dysfunction: conscious and nonconscious expression in impulsiveness and decision-making.

Authors:  T Palomo; R J Beninger; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2008-08       Impact factor: 3.911

Review 10.  Developing translational animal models for symptoms of schizophrenia or bipolar mania.

Authors:  M A Geyer
Journal:  Neurotox Res       Date:  2008-08       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.